Renovorx (RNXT) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Renovorx in October 2026.
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Renovorx (RNXT) Stock Forecast
Analyst price target, next 12 months
$7.00
+446.9% vs today's $1.28
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Renovorx have a consensus 12-month target of $7.00, above the current price of $1.28.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 27 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Renovorx's stock, with a target price of $7, indicating significant growth potential.
Financial Health
Renovorx Inc is generating solid revenue and cash flow, with a high gross margin indicating effective cost management.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
